Report Overview

The US Myasthenia Gravis drugs market size is USD xx billion in 2019 and projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Myasthenia gravis (MG) is a long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness. Muscles of the eyes, face, and swallowing are the most affected muscles in the body. The weakening of these muscles can result in double vision, drooping eyelids, trouble talking, and trouble walking. Although a rare disease, the prevalence of the disease has increased over the past few decades, as per National Organization for Rare Disorders. As a result, the research and development in understanding the disease and finding a cure have also increased and have helped this market to grow



Market Drivers

Advances in technology has resulted in development of therapeutics that are more effective as compared to traditional medicines. At the same time, increased level of awareness among patients and government support in product research & development is expected to create market opportunities in forthcoming years